19.07.2022
Acino donates for humanitarian aid in Ukraine
The war in Ukraine means that many Ukrainian people have been displaced and have no longer access to such essentials,...
News
30.06.2022
Meet Michael Zehringer, Team Lead Stability
Dedication and expertise are key qualities necessary to provide flexible solutions to our customers, and we are lucky to have...
14.06.2022
Acino signs exclusive license agreement with Bioprojet for treatment of narcolepsy and obstructive sleeping apnoea (OSA)
This agreement strengthens Acino’s position in the Central Nervous System (CNS) therapeutic area and paves the way for greater patient...
19.04.2022
Acino achieves Level 1 B-BBEE status in South Africa for the third year running
For the third year running, Acino has attained Level 1 B-BBEE status in South Africa. The Broad Based Black Economic...
12.04.2022
Acino and Batterjee Pharma sign partnership agreement to support Saudi Arabia’s Health Sector Transformation Programmme
The agreement between Acino and Batterjee covers the licensing, manufacturing, and supply of select Acino products across the Kingdom, based...
06.04.2022
Acino and Alpha Pharma team up to further the goals of Saudi Arabia’s Health Sector Transformation Programme
The agreement between Acino and Alpha Pharma covers the licensing, manufacturing, and supply of select Acino products across the Kingdom,...
30.03.2022
Acino strengthens operations in Saudi Arabia following sustained growth in the Middle East and Africa
Swiss pharma company plans to bring high-quality affordable medicines to patients in the kingdom, as part of its ongoing global...
16.03.2022
Resilience of the Ukrainian colleagues
At Acino, we express our unwavering support for our colleagues, patients and customers in Ukraine, many of whom continue to...
01.03.2022
Acino condemns the military actions in Ukraine
“I would like to express my deepest sadness and horror about the unfolding tragic events in Ukraine. Our thoughts and...